KyungDong Pharm home
Prescription Medicines

Aepen SR Tab.

Product Category
central muscle relaxant
Active Ingredients
Eperisone hydrochloride
Appearance
A white to almost white, round, extended-release, film-coated tablet.
Reimbursement Code
648104410
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Eperisone hydrochloride (KP) --- 75.0mg
- Additives (animal-derived ingredients): Magnesium stearate (beef, beef tallow)
- Other additives: Microcrystalline cellulose, citric acid hydrate, sodium starch glycolate, colloidal silicon oxide, Tabshield White (11W001), hypromellose

2. Effectiveness
Painful muscle spasms accompanying musculoskeletal diseases: glenohumeral syndrome, periarthritis of the shoulder, back pain

3. Dosage and dosage
This medicine is an extended-release tablet, so take it whole without crushing, splitting, or chewing.
Adults: Administer orally twice a day, 1 tablet (75 mg as eperisone hydrochloride) after meals.
Increase or decrease appropriately depending on age and symptoms.

4. Precautions for use
1. Do not administer to the following patients:
1) Patients with hypersensitivity to this drug
2) Patients with severe myasthenia gravis

2. Administer with caution to the following patients.
1) Patients with a history of drug hypersensitivity
2) Patients with hepatic impairment (can worsen liver function)

3. Adverse reactions
3.1 Adverse reactions reported in general eperisone hydrochloride tablets
1) Shock and anaphylactoid reactions: Shock and anaphylactoid reactions may occur in rare cases, so observe thoroughly and if symptoms (e.g. redness, itching, hives, edema, difficulty in breathing, etc.) appear, stop administration and take appropriate measures.
2) Toxic epidermal necrolysis (Riel syndrome) and mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome): Since eperisone hydrochloride can cause serious skin abnormalities such as toxic epidermal necrolysis and mucocutaneous ophthalmic syndrome, the patient must be closely observed for symptoms such as fever, erythema, blisters, itching, redness of the eye, and stomatitis. If these symptoms appear, stop administration and take appropriate measures.
3) Other adverse reactions
*Table: refer to manual
3.2 Adverse reactions of eperisone hydrochloride sustained-release tablets
1) In a randomized, double-blind, active-controlled, parallel-group clinical trial (n=238) targeting patients with symptoms of musculoskeletal muscle spasm accompanied by acute back pain, a total of 12 adverse reactions occurred, and the incidence rate was 5.26% (6/114 patients, 6 cases) in the test group (extended-release tablets) and 4.84% (6/124 patients) in the control group (regular tablets). 6 cases) were investigated. No serious adverse reactions were reported in both the test and control groups. As a result of analyzing the incidence of adverse drug reactions for which a causal relationship with the clinical drug could not be ruled out, the test group was 1.75% (2/114 people, 2 cases) and the control group was 0.81% (1/124 people, 1 case).
The only adverse reaction with a frequency of more than 2% was dizziness (2.63%).
The adverse reactions reported in the treatment group and control group during clinical trials are listed by organ of expression as follows.
<Status of adverse reactions by type>
*Table: refer to manual
2) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,247 people over 4 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 8.59% (279/3,247 people, 412 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
*Table: refer to manual
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to their frequency of occurrence.
*Table: refer to manual
3.3 The adverse cases identified as a result of analysis and evaluation of serious adverse events collected after domestic marketing are as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
• Immune system: Anaphylactic reaction
3.4 As a result of analysis and evaluation of clue information based on adverse event reporting data after drug marketing (1989-December 2018), the newly confirmed adverse cases are as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
• Skin and subcutaneous tissue - angioedema

4. General precautions
1) While taking this drug, lethargy, grogginess, drowsiness, etc. may occur. In such cases, reduce the dose or stop taking the drug.
2) Because drowsiness and a decrease in attention, concentration, reflexes, etc. may occur, patients taking this drug should be careful not to operate dangerous machinery, such as driving a car.

5. Interaction
There have been reports of visual acuity disorders when used together with tolperisone hydrochloride, a similar drug, and methocarbamol.

6. Administration to pregnant and lactating women
1) Since the safety of administration during pregnancy has not been established, it should be administered to pregnant women or women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks.
2) It is advisable to avoid administration to nursing mothers, but if administration is unavoidable, discontinue breastfeeding.

7. Administration to children
Safety for children has not been established (there is little experience with use).

8. Administration to elderly people
In general, elderly people have reduced physiological function, so be careful about reducing the amount.

9. Information for experts
1) Pharmacological action
Eperisone hydrochloride is a central muscle relaxant and is used to treat muscle spasms or spasticity in patients with neuromuscular disorders.

2) Pharmacokinetic information Note 1)
(1) Comparison of pharmacokinetic characteristics with immediate-release formulations
A. Single dose
As a result of comparing and evaluating pharmacokinetic indices after administering 1 tablet of eperisone hydrochloride sustained-release tablet 75 mg twice a day and 1 tablet of eperisone hydrochloride immediate-release 50 mg tablet 3 times a day to 25 healthy adult men (2 and Tmax was 2.92 hours, which was delayed compared to the immediate-release agent.
B. Repeated administration
To 25 healthy adult men, one tablet of eperisone hydrochloride sustained-release tablet 75 mg twice a day and one tablet of eperisone hydrochloride immediate-release tablet 50 mg three times a day were administered repeatedly after meals for 5 days. As a result of comparing and evaluating pharmacokinetic indices in steady state (2×2 crossover test), log-transformed AUCtau and Css,max between groups (test drug/control drug) The point estimates of the ratio were 0.85 and 0.79, respectively, and the Tmax was 2.84 hours, which was delayed compared to the immediate-release agent.
(2) Dietary impact assessment
As a result of comparing and evaluating the pharmacokinetic indices of 75 mg of eperisone hydrochloride sustained-release tablet administered once a day on an empty stomach and after a high-fat meal to 27 healthy adult men (2 It was 1.11, and Tmax increased to 3.3 hours compared to fasting.
3) Clinical trial information
In a multicenter, randomized, double-blind, parallel clinical trial targeting 238 patients with acute low back pain, oral administration of eperisone hydrochloride extended-release tablets 75 mg twice daily was compared with oral administration of eperisone hydrochloride immediate-release tablets 50 mg three times daily. The test group had a greater muscle relaxation effect than the control group, as assessed by the change in finger-to-floor distance (FFD) at 7 days compared to baseline. Non-inferiority was proven.
Note 1) This drug was manufactured by Aju Pharmaceutical Co., Ltd. using the same raw materials as Exxon SR Tablet (eperisone hydrochloride) and the entire process was outsourced to Aju Pharmaceutical Co., Ltd. using the same manufacturing method.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 500 tablets/bottle

7. Period of use
24 months from date of manufacture